Digestive Enzymes and Enzyme Therapy: Supporting Gut Health
By Julia Haimovich, Accredited Practising Dietitian.
Visit Julia’s website for lots of great information about nutrition and dietetics.
Digestive enzymes are indispensable for human nutrition because they ensure that food is broken down into smaller molecules that the body can absorb. When these enzymes are insufficient, whether due to pancreatic dysfunction, gastrointestinal disease, or intolerances, digestion is compromised, often leading to nutrient malabsorption, abdominal discomfort, and a decline in overall well-being. To address these issues, digestive enzyme therapy has gained recognition as an effective treatment option for several conditions where endogenous enzyme activity is impaired.
A review by de la Fuente and colleagues (2021) described both the benefits and obstacles associated with enzyme therapy, noting that advances in formulation and biotechnology are gradually improving its clinical value [1]. Enzymes such as amylases, proteases, and lipases, secreted by the pancreas, stomach, and small intestine, are responsible for digesting carbohydrates, proteins, and fats, respectively. Their efficient action is fundamental for nutrient uptake, energy balance, and gastrointestinal comfort, and when absent, supplementation may become essential.
Several medical conditions benefit directly from enzyme replacement. Pancreatic exocrine insufficiency, often linked to chronic pancreatitis, cystic fibrosis, or pancreatic surgery, leads to fat maldigestion, nutrient loss, and weight decline. Pancreatic enzyme replacement therapy (PERT) is the standard treatment and restores digestive function in these patients [2,3]. Lactose intolerance is another example, caused by reduced lactase activity in the small intestine, where oral lactase supplementation allows improved tolerance of dairy products and relief from symptoms [4]. In coeliac disease, oral gluten-degrading enzymes have been investigated as supportive therapies alongside a strict gluten-free diet, and in irritable bowel syndrome, specially designed enzyme blends that assist in breaking down FODMAP carbohydrates have shown potential to reduce gas, bloating, and abdominal pain [5,6].
Although effective, enzyme therapy is not without its limitations. A major obstacle is acid instability, as many enzymes are rapidly degraded in the stomach’s acidic environment. For this reason, protective technologies such as enteric coatings or microencapsulation are often needed to ensure that enzymes reach the small intestine intact [1,7]. Enzymes also act for a limited time and therefore must be taken repeatedly with meals, which may affect adherence in the long term. Another consideration relates to the sources of enzymes, since animal and microbe-derived products may raise ethical questions or pose risks of hypersensitivity in some individuals [1,8].
Encouragingly, modern advances are addressing many of these concerns. Microencapsulation and improved coating methods are helping enzymes survive gastric conditions and release effectively in the intestines. Recombinant enzyme technology, which produces enzymes through genetic engineering, is now delivering highly pure and consistent products with reduced risk of immune reactions compared with traditional sources [1,9]. Researchers are also developing formulations that activate only under specific pH or substrate conditions, thereby improving precision and minimising unwanted effects [9].
Looking ahead, personalised medicine is expected to shape the future of enzyme therapy. Emerging evidence suggests that tailoring enzyme formulations to a patient’s unique enzyme profile and gut microbiota could yield superior outcomes. Combining enzyme replacement with other functional compounds, such as prebiotics and probiotics, may further enhance gut health, improve nutrient absorption, and support long-term digestive resilience [1,10].
In conclusion, digestive enzyme therapy plays an essential role in the management of enzyme-related gastrointestinal disorders. While traditional formulations have provided significant clinical benefit, ongoing innovations in delivery systems and biotechnology are making enzyme treatments safer, more efficient, and increasingly tailored to the individual. As research continues to evolve, enzyme therapy is poised to expand its role in digestive health and overall well-being.
References
- de la Fuente M, Lombardero L, Gómez-González A, Solari C, Angulo-Barturen I, Acera A, et al. Enzyme Therapy: Current Challenges and Future Perspectives. Int J Mol Sci. 2021;22(17):9181. doi:10.3390/ijms22179181
- Domínguez-Muñoz JE. Pancreatic enzyme therapy for pancreatic exocrine insufficiency. Curr Gastroenterol Rep. 2007;9(2):116–22.
- Othman MO, Harb D, Barkin JA. Introduction and practical approach to exocrine pancreatic insufficiency for the practising clinician. Int J Clin Pract. 2018;72(2):e13066.
- Swagerty DL Jr, Walling AD, Klein RM. Lactose intolerance. Am Fam Physician. 2002;65(9):1845–50.
- Makharia GK, Verma AK, Amarchand R, et al. Prevalence of irritable bowel syndrome: A community-based study from Northern India. J Neurogastroenterol Motil. 2011;17(1):82–7.
- Tye-Din JA, Stewart JA, Dromey JA, et al. Comprehensive, quantitative mapping of T cell epitopes in gluten in coeliac disease. Sci Transl Med. 2010;2(41):41ra51.
- McConnell EL, Fadda HM, Basit AW. Gut instincts: Explorations in intestinal physiology and drug delivery. Int J Pharm. 2008;364(2):213–26.
- Whitcomb DC. Clinical practice. Acute pancreatitis. N Engl J Med. 2006;354(20):2142–50.
- Bleuez C, Koch WF, Urbach C, Hollfelder F, Jermutus L. Exploiting protease activation for therapy. Drug Discov Today. 2022;27(6):1743-1754.
- Wegh CA, Geerlings SY, Knol J, Roeselers G, Belzer C. Postbiotics and their potential applications in early life nutrition and beyond. Int J Mol Sci. 2019;20(19):4673.
